{"id":"low-dose-ruxolitinib","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Anemia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting JAK1 and JAK2, ruxolitinib reduces the production of pro-inflammatory cytokines and mediators, leading to anti-inflammatory effects. This mechanism is particularly beneficial in treating conditions characterized by excessive immune activation, such as myeloproliferative neoplasms.","oneSentence":"Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in signaling pathways involved in inflammation and immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:37.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelofibrosis"},{"name":"Polycythemia vera"}]},"trialDetails":[{"nctId":"NCT07498205","phase":"PHASE4","title":"Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-08-08","conditions":"Myelofibrosis, Myelofibrosis (MF)","enrollment":268},{"nctId":"NCT06327100","phase":"PHASE1, PHASE2","title":"Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-01","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis","enrollment":33},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT07249346","phase":"PHASE2","title":"Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hannah Choe, MD","startDate":"2026-06-01","conditions":"Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia","enrollment":124},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT07252050","phase":"PHASE1, PHASE2","title":"Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-01-01","conditions":"Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant","enrollment":24},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT05132166","phase":"PHASE2","title":"A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-22","conditions":"Graft Vs Host Disease","enrollment":50},{"nctId":"NCT04838704","phase":"NA","title":"Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-04-01","conditions":"Graft Versus Host Disease","enrollment":215},{"nctId":"NCT06457425","phase":"PHASE2","title":"A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-05-06","conditions":"MF,PMF,PPV-MF,PET-MF","enrollment":75},{"nctId":"NCT01895842","phase":"PHASE1","title":"Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-02","conditions":"Leukemia","enrollment":31},{"nctId":"NCT03773107","phase":"PHASE1, PHASE2","title":"LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":12},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT05600855","phase":"PHASE2","title":"Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-01-15","conditions":"Transplant-Related Disorder","enrollment":115},{"nctId":"NCT05599256","phase":"PHASE2","title":"Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-09","conditions":"Transplant-Related Disorder","enrollment":40},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT03144687","phase":"PHASE2","title":"A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-01-26","conditions":"MPN (Myeloproliferative Neoplasms)","enrollment":23},{"nctId":"NCT04397367","phase":"PHASE1, PHASE2","title":"Low Dose Ruxolitinib in Combination With Methylprednisolone","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2019-01-01","conditions":"aGVHD, Stem Cell Transplant Complications","enrollment":38},{"nctId":"NCT05039580","phase":"PHASE4","title":"Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-05-15","conditions":"EBV Infection","enrollment":36},{"nctId":"NCT04120090","phase":"PHASE3","title":"Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2019-07-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":80},{"nctId":"NCT02267278","phase":"PHASE2","title":"Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-12","conditions":"Myeloproliferative Diseases","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"low dose ruxolitinib","genericName":"low dose ruxolitinib","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in signaling pathways involved in inflammation and immune responses. Used for Myelofibrosis, Polycythemia vera.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}